The effect of benralizumab on inflammation in severe asthma: a real-life analysis

Background: Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its correlation with lung function. Objectives: The aim of the present study is to assess its effect after 1 year of treatment, focusing on a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Therapeutic advances in respiratory disease Jg. 18; S. 17534666241304685
Hauptverfasser:	Visca, Dina, Ardesi, Francesco, Zappa, Martina, Grossi, Sarah, Pignatti, Patrizia, Vanetti, Marco, Pini, Laura, Sotgiu, Giovanni, Centis, Rosella, Migliori, Giovanni Battista, Spanevello, Antonio
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London, England SAGE Publications 01.01.2024 SAGE PUBLICATIONS, INC SAGE Publishing
Schlagworte:	Adult Aged Anti-Asthmatic Agents - pharmacology Anti-Asthmatic Agents - therapeutic use Antibodies, Monoclonal, Humanized - pharmacology Antibodies, Monoclonal, Humanized - therapeutic use Asthma Asthma - diagnosis Asthma - drug therapy Asthma - physiopathology Eosinophils - drug effects Female Forced Expiratory Volume Humans Inflammation Italy Lung - drug effects Lung - immunology Lung - physiopathology Male Middle Aged Monoclonal antibodies Original Research Pulmonary Eosinophilia - diagnosis Pulmonary Eosinophilia - drug therapy Pulmonary Eosinophilia - immunology Pulmonary Eosinophilia - physiopathology Quality of Life Retrospective Studies Severity of Illness Index Sputum - cytology Sputum - immunology Time Factors Treatment Outcome Italy airway inflammation disease control induced sputum severe asthma lung function benralizumab
ISSN:	1753-4666, 1753-4658, 1753-4666
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!